Recent Analysts’ Ratings Changes for Myriad Genetics (MYGN)

Several analysts have recently updated their ratings and price targets for Myriad Genetics (NASDAQ: MYGN):

  • 11/12/2026 – Myriad Genetics had its price target raised by Stephens from $3.00 to $6.00. They now have an “equal weight” rating on the stock.
  • 11/12/2026 – Myriad Genetics had its price target raised by Stephens from $3.00 to $6.00. They now have an “equal weight” rating on the stock.
  • 11/7/2026 – Myriad Genetics was upgraded by Wall Street Zen from “sell” to “hold”.
  • 11/5/2026 – Myriad Genetics had its price target raised by TD Cowen from $4.50 to $6.75. They now have a “hold” rating on the stock.
  • 11/5/2026 – Myriad Genetics had its price target raised by Leerink Partners from $5.00 to $8.00. They now have a “market perform” rating on the stock.
  • 10/27/2026 – Myriad Genetics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 10/20/2026 – Myriad Genetics was given a new $4.50 price target by Wells Fargo & Company.
  • 10/20/2026 – Myriad Genetics was upgraded by Piper Sandler from “underweight” to “neutral”. They now have a $5.00 price target on the stock.
  • 10/15/2026 – Myriad Genetics was upgraded by Zacks Research from “strong sell” to “hold”.
  • 10/13/2026 – Myriad Genetics had its price target raised by TD Cowen from $4.00 to $4.50. They now have a “hold” rating on the stock.
  • 10/12/2026 – Myriad Genetics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 10/2/2026 – Myriad Genetics had its price target raised by Craig Hallum from $4.00 to $8.00. They now have a “buy” rating on the stock.

Myriad Genetics Stock Performance

NASDAQ:MYGN opened at $5.66 on Monday. The company has a quick ratio of 1.77, a current ratio of 1.98 and a debt-to-equity ratio of 0.45. Myriad Genetics, Inc. has a twelve month low of $2.74 and a twelve month high of $8.09. The company has a fifty day moving average of $4.75 and a 200-day moving average of $4.62. The firm has a market capitalization of $542.91 million, a P/E ratio of -4.16 and a beta of 1.62.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. Myriad Genetics had a negative return on equity of 19.87% and a negative net margin of 16.07%. The company had revenue of $202.70 million for the quarter, compared to analyst estimates of $191.33 million. As a group, sell-side analysts anticipate that Myriad Genetics, Inc. will post -1.02 EPS for the current year.

Myriad Genetics, Inc. is a molecular diagnostics company that develops and provides genetic tests to help inform healthcare decisions. Its offerings include tests for hereditary cancer risk, tumor biology and prognosis, reproductive health, and how patients may respond to certain medications. Its products include MyRisk, which assesses inherited cancer risk; GeneSight, a pharmacogenomic test intended to help guide psychiatric medication decisions; and Prolaris, which helps assess the aggressiveness of prostate cancer.

Read More

Receive News & Ratings for Myriad Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.